|Articles|March 4, 2008

ADHD Stimulants Not Related to Drug Abuse

The use of stimulant treatment in male children with attention-deficit/hyperactivity disorder (ADHD) wasn't associated with an increased or decreased risk of later substance use disorder, according to research published online March 3 in the American Journal of Psychiatry.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Parent smartphone use linked to slower vocabulary growth in young children | Image Credit: © Halfpoint - stock.adobe.com

Parent smartphone use linked to slower vocabulary growth in young children

ByMorgan Ebert, Executive Editor

August 24th 2026

Collaborative care program increases pediatricians’ confidence in managing pediatric mental health

Collaborative care program increases pediatricians’ confidence in managing pediatric mental health

ByJohn T. Parkhurst, PhD

August 6th 2026

CTx-1301 improves pediatric ADHD symptoms in phase 3 trial | Image Credit: © Tiara - stock.adobe.com.

CTx-1301 improves pediatric ADHD symptoms in phase 3 trial

ByContemporary Pediatrics Staff

July 30th 2026

Late preterm hypoglycemia not linked to neurodevelopment at age 6 | Image Credit: © Goffkein - stock.adobe.com

Late preterm hypoglycemia not linked to neurodevelopment at age 6

ByJoshua Fitch, Senior Editor

July 29th 2026

FDA approves centanafadine for ADHD in children, adolescents, and adults

FDA approves centanafadine for ADHD in children, adolescents, and adults

ByMorgan Ebert, Executive Editor

July 27th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

FAQ: What's new in COVID-19, RSV, and flu guidance?

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

Teen sports supplements: What to recommend, use with caution, and avoid

FDA approves leniolisib for children aged 4 to 11 with APDS

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy